Evidence map›Paper›PMID 35687212›Full record

ArticlePurinergic signalling2023

Fluorescent A

Kiran S Toti, Ryan G Campbell, Hobin Lee, Veronica Salmaso, R Rama Suresh, Zhan-Guo Gao, Kenneth A Jacobson

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Purinergic signalling, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Journal of medicinal chemistry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kiran S TotiMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, NIH, NIDDK, LBC, Bldg. 8A, Rm. B1A-19, Bethesda, MD, 20892-0810, USA.
Ryan G CampbellMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, NIH, NIDDK, LBC, Bldg. 8A, Rm. B1A-19, Bethesda, MD, 20892-0810, USA.
Hobin LeeMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, NIH, NIDDK, LBC, Bldg. 8A, Rm. B1A-19, Bethesda, MD, 20892-0810, USA.
Veronica SalmasoMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, NIH, NIDDK, LBC, Bldg. 8A, Rm. B1A-19, Bethesda, MD, 20892-0810, USA.
R Rama SureshMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, NIH, NIDDK, LBC, Bldg. 8A, Rm. B1A-19, Bethesda, MD, 20892-0810, USA.
Zhan-Guo GaoMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, NIH, NIDDK, LBC, Bldg. 8A, Rm. B1A-19, Bethesda, MD, 20892-0810, USA.
Kenneth A JacobsonMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, NIH, NIDDK, LBC, Bldg. 8A, Rm. B1A-19, Bethesda, MD, 20892-0810, USA. kennethj@niddk.nih.gov.ORCID 0000-0001-8104-1493
National Institutes of Health · US

Funding

Development Of Drugs Acting At Adenosine ReceptorsZIADK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$10.4M
Computer Modeling of G Protein-Coupled ReceptorsZIADK031126 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$6.6M
Functionalized Congeners Of Bioactive CompoundsZIADK031115 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$5.3M
Intramural NIH HHS ZIA DK031117NIDDK NIH HHS ZIADK031117
6 · The paper itself

Abstract

Adenosine receptor (AR) ligands are being developed for metabolic, cardiovascular, neurological, and inflammatory diseases and cancer. The ease of drug discovery is contingent on the availability of pharmacological tools. Fluorescent antagonist ligands for the human A

Indexed as

Fluorescent DyesPurinergic P1 Receptor AntagonistsAdenosine A2 Receptor AntagonistsAminesFlow CytometryHEK293 CellsHumansReceptor, Adenosine A2AReceptor, Adenosine A3Adenosine A2 Receptor AntagonistsAminesFluorescent DyesPurinergic P1 Receptor AntagonistsReceptor, Adenosine A2AReceptor, Adenosine A3Adenosine receptorAntagonistDrug discoveryFlow cytometryFluorescent ligandsReceptor binding

Identifiers

PMID35687212
PMCPMC10539269
OpenAlexW4281765584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.